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Abstract 
BACKGROUND: Type 2 Diabetes Mellitus is one of the most common metabolic diseases worldwide. The most 
common complication of DM is diabetic neuropathy (DN), especially diabetic polyneuropathy (DPN). Vitamin D 
plays an important role in the pathogenesis of DN, thus affecting its severity which can be assessed using nerve 
conduction study (NCS). 
AIM: This study aimed to develop a predictive model of DPN severity based on vitamin D level.  
METHODS: This was a prospective cohort study involving 50 subjects with DM which was conducted in Haji 
Adam Malik General Hospital Medan. All subjects were fulfilling inclusion criteria underwent laboratory 
examination to determine HbA1c and 25 (OH) D levels. Predictive variables were sex, age, duration of DM, 
smoking status, type and number of anti-diabetic drugs, the presence of metabolic syndrome, HbA1c and vitamin 
D levels. A scoring system was developed to determine a predictive model. The DPN severity was assessed 
using NCS and was re-evaluated after 3 months.  
RESULTS: Most of the subjects were female (60%), belonged to ≥ 50 years old age-group (88%), with DM 
duration < 5 years (56%), were non-smoker (90%), we're using one anti-diabetic drug (60%), were using insulin 
(50%), had metabolic syndrome (68%), had HbA1c level > 6.5% (94%), and had vitamin D level < 20 ng/ml (56%). 
A score of > 4 on this predictive model of DPN severity had a relative risk (RR) of 2.70. The predictive model had 
a sensitivity of 82.8% and specificity of 61.9%.  
CONCLUSION: A score of higher than 4 on this predictive model showed a 2.7 times higher risk of severe DPN. 
A predictive model of DPN severity based on vitamin D level had high sensitivity and specificity. 
 
 
 
Introduction 
 
Diabetic neuropathy (DN) is the most 
common complication of diabetes mellitus (DM) [1], 
[2]. Its prevalence is high in developed countries. It is 
related to greater mortality, morbidity and higher 
economic burden and rate of hospitalisations [3], [4]. 
Chronic diabetic polyneuropathy (DPN) is the most 
common type of DN, accounting for about 75% of DN 
[5], [6]. American Diabetic Association recommends 
that all diabetic patients should be screened for DN at 
the time of diagnosis in type 2 DM and five years after 
diagnosis of type 1 DM [3], [7]. Once established, 
neuropathy is difficult to reverse [4]. Neurological 
examinations and careful evaluation of neuropathic 
signs and symptoms are important in early detection 
and severity determination [8]. Nerve conduction 
study (NCS) can detect neural changes even before 
the sign develops and determine the severity of 
neuropathy [9]. 
Vitamin D may have a direct effect on the 
pathogenesis of DN, particularly vitamin D3 that has 
been shown the ability to reduce demyelination in an 
experimental model [10]. Serum 25-hydroxyvitamin D 
(25 (OH) D) is the major circulating form of vitamin D. 
Some studies showed vitamin 25 (OH) D deficiency is 
associated with DPN [11], [12]. In Asian, diabetic 
patients with vitamin D deficiency are 1.22 times more 
likely to suffer from DPN compared with those with 
normal vitamin D level [13]. 
The aim of this study was mainly to develop a 
predictive model of DPN severity based on vitamin D 
level, that can be clinically used for early detection, 
severity prevention of DPN so the treatment can be 
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optimised and may improve the quality of life of type 2 
DM patients.  
 
 
Material and Methods 
 
This was a prospective cohort study which 
was conducted in Haji Adam Malik General Hospital 
Medan and had been approved by the Local Ethical 
Committee. Inclusion criteria were typed 2 DM 
patients with DPN. Exclusion criteria were patients 
with impaired renal or hepar function, consumption of 
anti-tuberculous drugs or chemotherapy. All subjects 
signed an informed consent before the examination. 
We recorded data from the subjects such as sex, age, 
duration of DM, smoking status, type and number of 
anti-diabetic drugs, and the presence of the metabolic 
syndrome. All subjects underwent NCS examination 
by the same neurologist using Cadwell ENMG 
(electroneuromyography) machine. HbA1c level was 
evaluated using the enzyme immunoassay method, 
and serum vitamin 25 (OH) D status was evaluated 
using the chemiluminescent immunoassay method. 
The NCS was repeated after 3 months to assess DPN 
severity.  
The predictive variables consisted of 
demographic and clinical data, combined with HbA1c 
and vitamin 25(OH)D levels. Results of NCS after 3 
months were classified using Baba’s Diabetic 
Neuropathy Classification (BDC), consisted of BDC-0: 
no NCS abnormalities, BDC-1: delay in any MCV, 
SCV, BDC-2: sural amplitude < 5 µV, BDC-3: plantar 
muscle-CMAP amplitude to 2 – 5 mV, BDC-4: plantar 
muscle-CMAP < 2 mV.
14
 We classified BDC-1 was 
mild and BDC-2 – 4 was severe. A scoring system 
was developed; the total value was 0 – 12.  
The predictive variables were categorical 
data. The predictive variables as independent 
variables and DPN severity as a dependent variable. 
The association of predictive factors and score with 
DPN severity was assessed using a Chi-Square Test 
or Fisher’s Test. The results were considered 
significant at p < 0.05. Risk Ratio (RR) for each group 
was calculated. The statistical calculations were done 
using the computerized program. 
 
 
Results 
 
There were 50 patients included in this study. 
Age, sex, ethnicity, duration of diabetes and glycemic 
control are established risk factor for DN [15]. High 
body mass index, hypertension and smoking are 
established risk factors for DN [16]. Age, an insulin 
treatment, longer duration of DM, and higher HbA1c 
were independently significant risk factors for DPN 
[17]. Metabolic syndrome, including pre-diabetes, are 
potential risk factors for neuropathy [18], [19]. Skalli et 
al. ’s study (2012) found diabetic neuropathy was 
significantly linked to age, diabetes duration, and 
vitamin D status [12]. 
Based on previous studies, we selected some 
risk factors to be the predictive factors. The predictive 
factors consisted of sex, age, duration of DM, smoking 
status, type and number of anti-diabetic drugs, the 
presence of metabolic syndrome, HbA1c and vitamin 
25(OH)D levels. A scoring system is shown in Table 
1. 
Table 1: The Predictive Score 
Characteristics Parameters Score 
Sex Male 
Female 
0 
1 
Age group (years) < 50 
> 50 
0 
1 
Duration of DM (years) < 5 
≥ 5 
0 
1 
Smoking status No 
Yes 
0 
1 
Number of anti-diabetics 1 
> 1 
0 
1 
Type of anti-diabetic Insulin 
Oral 
Combination 
0 
1 
2 
Metabolic syndrome No 
Yes 
0 
1 
HbA1c levels (%) < 6.5 
≥ 6.5 
0 
1 
Vitamin 25 (OH) D levels 
(ng/ml) 
≥ 30 
20–29.9 
10–19.9 
< 10 
0 
1 
2 
3 
Total  0 – 12 
 
As shown in Table 2, most of the subjects 
were female (30 subjects, 60%), 44 subjects (88%) 
belonged to ≥ 50 years old age-group, 28 subjects 
(56%) with DM duration < 5 years, 45 subjects (90%) 
were non-smoker, 30 subjects (60%) were using one 
anti-diabetic drug, 25 subjects (50%) were using 
insulin, 34 subjects (68%) had metabolic syndrome, 
47 subjects (94%) had HbA1c level ≥ 6,5%, and 28 
subjects (56%) had vitamin 25(OH)D level < 20 ng/ml.  
Table 2: Association of Predictive Factors with DPN Severity 
Predictive Factors DPN severity p RR 95% CI 
Mild Severe 
Sex 
Male 
Female 
 
10 
11 
 
10 
19 
0.349a 1.73 0.50–6.19 
Age group (years) 
< 50 
≥ 50 
 
3 
18 
 
3 
26 
0.499b 0.69 0.12–3.85 
Duration of DM (years) 
< 5 
≥ 5 
 
17 
4 
 
11 
18 
0.002a* 0.14 0.03–0.49 
Smoking status 
No 
Yes 
 
21 
0 
 
24 
5 
0.056b 1.88 1.47–2.61 
Number of anti-diabetics  
1 
> 1 
 
14 
7 
 
16 
13 
0.413a 1.63 0.55–6.22 
Type of anti-diabetic 
Insulin 
Oral 
Combination 
 
11 
9 
1 
 
14 
12 
3 
 
 
0.483a 
0.938b 
 
 
2.36 
1.05 
 
 
0.21–5.91 
0.33–3.38 
Metabolic syndrome 
No 
Yes 
 
8 
13 
 
8 
21 
0.432a 0.62 0.17–2.19 
HbA1c (%) 
< 6,5 
≥ 6,5 
 
1 
20 
 
2 
27 
0.621b 1.48 0.19–4.18 
25 (OH) D (ng/ml) 
< 20 
≥ 20 
 
11 
10 
 
17 
12 
0.661a 0.78 0.23–2.59 
aChi-Square Test; bFisher’s Test; *p < 0.05; RR = a / (a + b): c / (c + d). 
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Our study found that it was a significant 
association between duration of DM and DPN 
severity. Most of the subjects with a duration of DM < 
5 years had mild DPN (17 subjects, 60.7%), but most 
of them with a duration of DM ≥ 5 years had severe 
DPN (18 subjects, 62.1%). 
Table 3: Proportion Vitamin 25 (OH) D Level 
Vitamin 25(OH)D Level (ng/ml) Frequency Percentage 
<10 (severe deficient) 2 4 
10–19.9 (deficient) 26 52 
20–29.9 (insufficient) 21 42 
>30 (adequate) 1 2 
 
In Table 3, almost all of the subjects had 
vitamin D deficiency (49 subjects, 98%). Most of them 
(26 subjects, 52%) had vitamin 25 (OH) D level 10 – 
19.9 ng/ml (deficient). 
In 3
rd
 month, approximately 29 subjects (58%) 
had severe DPN, which 14 subjects (28%) had BDC 
2. The proportion of DPN severity is shown in Table 4.  
Table 4: Proportion of DPN Severity 
DPN Severity Frequency Percentage 
Mild 
BDC 1 
 
21 
 
42 
Severe 
BDC 2 
BDC 3 
BDC 4 
 
14 
9 
6 
 
28 
18 
12 
 
The predictive model analysed by logistic 
regression and cutoff point on the ROC curve was 4 
(Figure 1). After 3 months, 24 subjects (75%) with 
predictive score > 4 had severe DPN and 13 subjects 
(72%) with predictive score ≤ 4 had mild DPN. The 
combination of predictive factors had strongly basic to 
estimate DPN severity after 3 months. The predictive 
model was more accurate than a predictive variable 
alone. 
 
Figure 1: ROC Curve for Predictive Model 
 
In Table 5, the predictive model had a 
sensitivity of 82.8% and specificity of 61.9%. Positive 
predictive value of 75%. Negative predictive value of 
72.2%. Subjects with a score > 4 on this predictive 
model of DPN severity had relative risk (RR) of 2.70, 
that showed 2.7 times higher risk of severe DPN after 
3 months. 
 
Table 5: Comparison between Predictive Score and DPN 
Severity 
 DPN Severity Total p RR 95% CI 
Severe Mild 
Predictive Score ≥ 4 24 8 32 0.001* 2.70 0.171–0.801 
≤ 4 5 13 18    
Total 29 21 50    
Chi-Square Test; *p < 0.05; RR = a / (a + b): c / (c + d). 
 
 
Discussion 
 
In this study, most of the subjects were 
female (60%) and belonged to ≥ 50 years old age-
group (88%), with DM duration < 5 years (56%), had 
metabolic syndrome (68%) and had HbA1c level ≥ 
6.5% (94%). Willer et al. ’s study (2016) found risk 
factor of type 2 DM and its complications which is 
obesity and psychosocial stress appears to have a 
greater impact on women rather than on men [20]. 
The DN is commonest after 5
th
 decade. Middle age / 
elderly diabetic was generally more affected [21]. 
Neuropathic symptoms increase with duration of DM 
[16], [21]. Some studies found a lower prevalence of 
DPN in those with duration < 5 years and the highest 
in those with duration > 15 years [7], [22]. 
Accumulating evidence suggests that the prevalence 
of DPN markedly elevated at the time of diabetes 
diagnosis [15]. Hyperglycemia, dyslipidemia, and 
metabolic syndrome have all been shown to initiate 
neuropathy through a common mechanism oxidative 
stress [15]. HbA1c as an indicator of glycemic control 
[22]. Poor glycemic control is regarded as the most 
important contributor to the mechanism of DN [11]. 
We found most of the subjects had vitamin 25 
(OH) D level < 20 ng/ml (56%). Vitamin 25 (OH) D 
might play a functional role in glucose homeostasis. 
Vitamin D has a potential impact on insulin secretion, 
insulin sensitivity, and subsequently on the incidence 
of DM [11]. Patients with vitamin D deficiency (25 
(OH) D < 20 ng/ml) had higher odds of having 
symptomatic DN than individuals with 25 (OH) D of 30 
– 40 ng/ml [11], [12]. Vitamin D might be implicated in 
DPN’s pathophysiology via its potential influence on 
nerve function [12]. 
In this study, most of the predictive factors 
were not significant association with DPN severity. But 
the combination of that variable in the predictive 
model was a significant association with DPN severity. 
On this predictive model of DPN severity, 
subjects with a score of higher than 4 had RR of 2.70, 
showed that had 2.7 times higher risk of severe DPN 
than a score of lower as 4 after 3 months. 
The predictive model had a sensitivity of 
82.8% and specificity of 61.9%. The sensitivity of 
82.8% was probability subjects had severe DPN with 
predictive score > 4 as 82.8%. The specificity of 
61.9% was probability subjects had mild DPN with 
predictive score ≤ 4 as 61.9%. Positive predictive 
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value of 75%, was probability subjects with predictive 
score > 4 had severe DPN as 75%. Negative 
predictive value of 72.2%, was probability subjects 
with predictive score ≤ 4 had mild DPN as 72.2%. 
In conclusion, a score of higher than 4 on this 
predictive model showed 2.7 times higher risk of 
severe DPN. A predictive model with using a scoring 
system in predicting DPN severity based on vitamin D 
level had high sensitivity and specificity.  
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